Clinical trials: Epilepsy (treatment Refractory)
Major Depressive Disorder, Suicide
Accelerated iTBS for Depression and Suicidality
The overall objective of this current study is to evaluate the feasibility, safety, and tolerability of "high dose" aiTBS in psychiatric inpatient and outpatients with treatment-refractory unipolar, non-psychotic major depressive…
- Trial name
- RAPID (NCT04441008)
- Testing
- Accelerated Intermittent Theta Burst (aiTBS), Electroconvulsive therapy (ECT)
- Volunteers
- 50 people
- Sponsor
- University of Iowa
Epilepsy (Treatment Refractory)
Determinants of Adaptive Behavior Through the Vineland Scale in Pediatric Patients With Severe and Drug-resistant Epilepsy
Our interest in studying how pediatric patients develop after epilepsy surgery stems from the fact that difficult-to-control epilepsy causes changes in the brain's formation or functioning, leading some patients to experience…
- Trial name
- NCT06832020
- Where
- Brazil
- Volunteers
- 369 people
- Sponsor
- Ana Valeria Duarte Oliveira
Epilepsy
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00175825
- Testing
- Brivaracetam
- Where
- 42 sites in United States, Brazil and 2 more
- Volunteers
- 210 people
- Sponsor
- UCB Pharma
Epilepsy, Temporal Lobe
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes…
- Trial name
- NCT06422923
- Testing
- NRTX-1001
- Where
- 17 sites in United States
- Volunteers
- 10 people
- Sponsor
- Neurona Therapeutics
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Hypoxic Brain Damage, Hypoxic Ischaemic Encephalopathy (HIE)
Intranasal AAV9-PHP.eB Gene Therapy in Cerebral Palsy (CP) & Hypoxic Ischemic Encephalopathy (HIE)
This international study, organized by Healing Hope International, is an observational registry designed to collect real-world data on participants living with chronic hypoxic ischemic encephalopathy (HIE) who receive an emerging…
- Conditions
- Hypoxic Brain Damage, Hypoxic Ischaemic Encephalopathy (HIE), Hypoxic Ischaemic Encephalopathy Due to Cardiac Arrest, Hypoxic Ischemic Encephalopathy of Newborn
- Trial name
- GEN-HOPE (NCT07264166)
- Where
- Mexico
- Volunteers
- 25 people
- Sponsor
- Healing Hope International
Refractory Partial Seizures
Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures
This study will evaluate the efficacy and safety of Rufinamide in reducing seizure frequency in subjects with partial seizures not fully controlled despite treatment with 1 to 3 concomitant antiepileptic drugs.
- Trial name
- NCT04558580
- Testing
- Rufinamide
- Where
- United States
- Sponsor
- University of South Alabama
Refractory Epilepsy, SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
Galactose Supplementation for the Treatment of MOGHE
Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a new entity frequently associated with refractory epilepsy and neurodevelopmental disorders.
- Trial name
- GATE (NCT04833322)
- Testing
- D-Galactose
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Hospital Ruber Internacional
Epilepsy Intractable
Effects of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Refractory Epilepsy
The aim of this study is to investigate the effects of cathodal transcranial direct current stimulation in the management of seizures in subjects with focal refractory epilepsy.
- Trial name
- NCT04325360
- Testing
- Cathodal Transcranial Direct Current Stimulation
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Campinas, Brazil
Tuberous Sclerosis Complex, Aspirin
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
There had been much evidence in aspirin controlling tumorous conditions conducted by basic researches, especially through mammilian target of rapamycin (mTOR) pathway.
- Conditions
- Tuberous Sclerosis Complex, Aspirin, Epilepsy, Cognitive Decline
- Trial name
- NCT03356769
- Testing
- Aspirin, AED
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Peking Union Medical College Hospital
Epilepsy, Partial
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152451
- Testing
- Seletracetam (ucb 44212)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- UCB S.A. - Pharma Sector
CDKL5 Deficiency Disorder
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation.
- Trial name
- Marigold (NCT03572933)
- Testing
- ganaxolone
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 101 people
- Sponsor
- Marinus Pharmaceuticals
Refractory Childhood Epilepsy
Cannabidiol for Pediatric Epilepsy (Compassionate Use)
This is an open-label observational study of pure CBD for the treatment for 25 children with intractable epilepsy. As pure CBD is not FDA approved, the investigators are conducting this study via the FDA expanded access mechanism…
- Trial name
- NCT02556008
- Testing
- cannabidiol (CBD)
- Where
- United States
- Sponsor
- University of California, Los Angeles
Epilepsy Intractable
Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs
This is an open label, randomized, prospective study of the impact on healthcare utilization of a surface Electromyography (sEMG) based seizure monitoring and alerting system for Veterans with seizures with upper extremity motor…
- Trial name
- NCT03741192
- Testing
- SPEAC System
- Volunteers
- 58 people
- Sponsor
- Brain Sentinel
Epilepsy
Clinical Trial of MgLiTT for Medical Refractory Epilepsy
Multicenter, open-label, prospective designed study to characterize the performance of MRI-guided laser interstitial thermal therapy (MgLiTT) using the Sinovation Laser Ablation System for the treatment of medical refractory…
- Trial name
- NCT04569071
- Testing
- Sinovation Laser Ablation System
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Beijing Tiantan Hospital
Epilepsy
A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093
The purpose of this study is to determine the efficacy of BIA 2 093 in the treatment of epileptic patients with refractory simple or complex partial seizures with or without secondary generalization.
- Trial name
- NCT02170077
- Testing
- BIA 2-093
- Where
- Portugal
- Volunteers
- 144 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy
The goal of the present study is to obtain pilot data on efficacy and safety of clobazam add-on treatment on adults with drug-resistant focal epilepsy.
- Trial name
- NCT02726919
- Testing
- Clobazam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pavel Klein
Refractory Focal Epilepsy
Slow Oscillatory Transcranial Direct Current Stimulation for Refractory Focal Epilepsy
This pilot study evaluated whether a type of non-invasive brain stimulation called slow-oscillatory transcranial direct current stimulation (so-tDCS) can reduce seizure frequency in patients with drug-resistant focal epilepsy.
- Trial name
- so-tDCS-RE (NCT07684352)
- Testing
- Slow-oscillatory transcranial direct current stimulation (so-tDCS)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Hospital of Hebei Medical University
Quality of Life, Epilepsy (treatment Refractory)
Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data
The study will be prospective, multicentre, postmarketing clinical study, with a controlled and randomized design, to perform the analysis of 130 subjects with a clinical diagnosis of epilepsy, patients whose clinical semiology…
- Trial name
- SERAS_Home_RWD (NCT05845255)
- Testing
- mjn-SERAS
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 130 people
- Sponsor
- MJN Neuroserveis, S.L
Dravet Syndrome
Stiripentol in Dravet Syndrome
The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome.
- Trial name
- NCT01533506
- Testing
- stiripentol
- Where
- United States
- Sponsor
- Mayo Clinic